dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 5/500 mg reference drug (Humacao) + dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioequivalence
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Trial Timeline
Dec 21, 2015 → Apr 7, 2016
NCT ID
NCT02637037About dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 5/500 mg reference drug (Humacao) + dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 5/500 mg reference drug (Humacao) + dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao) is a phase 1 stage product being developed by AstraZeneca for Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT02637037. Target conditions include Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02637037 | Phase 1 | Completed |
Competing Products
20 competing products in Bioequivalence